Regorafenib (LuciRegor) 40mg*28's | Lucius Laos Generic | GLT

REQUEST A QUOTE

For individuals and institutions — pricing, availability, and product documents (COA) provided within 24 hours.
Direct line: [email protected] · +86 15234153837

مشاركة
Product description

Generic Information: LuciRegor (Laos)

LuciRegor is a Laos-market brand of regorafenib manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd., a Lao pharmaceutical company focused on oncology medicines. Each pack contains 28 film-coated tablets of 40 mg. LuciRegor is an accessible option for patients with advanced colorectal cancer, gastrointestinal stromal tumour or hepatocellular carcinoma who need later-line multi-kinase therapy.

What Is Regorafenib (LuciRegor) Used For?

LuciRegor is used to treat metastatic colorectal cancer that has progressed after standard chemotherapy plus anti-VEGF and, where relevant, anti-EGFR therapy. It is also indicated for gastrointestinal stromal tumour resistant to imatinib and sunitinib, and for hepatocellular carcinoma that has progressed on sorafenib. It is a later-line disease-control therapy given once earlier treatments have stopped working.

How Does Regorafenib Work?

Regorafenib is a multi-kinase inhibitor that blocks the VEGF receptors 1, 2 and 3, TIE2, PDGFR-α and β, FGFR-1 and 2, KIT, RET, RAF-1 and BRAF. This broad action suppresses both the growth signals inside cancer cells and the signalling that drives new blood-vessel formation, so tumours are deprived of both the instructions to divide and the blood supply they need to survive and spread.

Indications

The three approved indications are advanced colorectal cancer after prior standard therapy, imatinib- and sunitinib-resistant gastrointestinal stromal tumour, and sorafenib-refractory hepatocellular carcinoma. An oncologist should initiate and monitor treatment, and liver function and blood pressure must be assessed before starting.

Dosage

The recommended dose is 160 mg (four 40 mg tablets) once daily with a low-fat meal, given in 28-day cycles of 21 days on and 7 days off. A 28-tablet pack supplies seven days of the active-treatment phase. The dose may be reduced to 120 mg or 80 mg daily to manage side effects such as hand-foot skin reaction or elevated liver enzymes.

Side Effects

The most frequent side effects are hand-foot skin reaction, diarrhoea, fatigue, high blood pressure, reduced appetite and mouth sores. Serious but uncommon effects include liver injury, bleeding, gastrointestinal perforation and cardiac problems. Liver function, blood pressure and blood counts should be monitored regularly, and patients should report skin changes, persistent diarrhoea, dark stools or chest pain promptly.

Storage

Store LuciRegor tablets at room temperature in the original container, protected from moisture, and out of the reach of children. Do not use past the expiry date on the pack.

Why Choose LuciRegor Through GLT?

LuciRegor provides overseas patients and institutions with a lower-cost regorafenib sourced from the Lao market, where manufacturing keeps pricing accessible. GLT verifies authenticity and ships worldwide from a Hong Kong-licensed facility, giving patients a dependable and affordable supply for longer-term later-line cancer treatment.

How to Order

To order LuciRegor (regorafenib) from GLT, contact us on WhatsApp at +86 15234153837 or by email at [email protected]. We will confirm current availability, pricing and delivery to your country, and we ship from a Hong Kong-licensed facility.

FAQ

Is LuciRegor the same as Stivarga? Yes — it contains the same regorafenib molecule, manufactured by Lucius Pharmaceuticals in Laos.

What is the dosing schedule? 160 mg once daily for 21 days, then a 7-day break, repeated every 28 days.

Do I need a prescription? Yes, regorafenib is prescription-only and requires a valid oncologist's prescription.

Related Oncology Products

مونجارو كويك بن (تيرزيباتيد) 10–60ملغ/2.4مل قلم متعدد الجرعات | إيلي ليلي (الولايات المتحدة) | GLT

مونجارو كويك بن — قلم إيلي ليلي متعدد الجرعات لمريض واحد، بست جرعات أمريكية (10–60ملغ/2.4مل،...

KangQuXin 康曲欣 (أفاترومبوباغ) 20 ملغ × 10 أقراص | Beijing Continent (Gyre) | GLT

KangQuXin — أفاترومبوباغ من Beijing Continent Pharmaceutical (Gyre Therapeutics، ناسداك: GYRE)، الصين

Rizonib (كريزوتينيب) كبسولات 250 ملغ | بديل Xalkori الجنيس من DIL بنغلاديش لسرطان الرئة ALK+ | GLT

Rizonib 250 من Drug International Ltd (DIL)، تونغي غازيبور — بديل كريزوتينيب جنيس ميسور التكلفة...

إلترومبوباغ (Promacta) أقراص 25/50 ملغ | ناهض TPO-R أصلي أمريكي | GLT

Promacta الأصلي من Novartis (إلترومبوباغ) 25 ملغ و50 ملغ، 30 قرصًا

كيزيروي 科瑞泽 (أفاترومبوباغ) 20ملغ*10 أقراص | سيتشوان كيلون (الصين) | GLT

كيزيروي — أفاترومبوباغ المشتريات الوطنية من سيتشوان كيلون للأدوية، الشركة الصينية المتكاملة لتصنيع المادة الفعالة...

XinKePing 欣可平 (أفاترومبوباغ) 20 مجم × 10 أقراص | Nanjing Hencer الصين | GLT

XinKePing — أفاترومبوباغ من Nanjing Hencer Pharmaceutical (مجموعة Jemcare)، بتكامل رأسي بين المادة الفعالة والأقراص،...

باريسينت (باريسيتينيب) 2ملغ | مثبط JAK1/JAK2 جنيس | إنسبتا للأدوية المحدودة | GLT

باريسيتينيب جنيس (مثبط JAK1/JAK2) من إنسبتا للأدوية المحدودة (بنغلاديش) — بديل ميسور التكلفة عن أولوميانت...

أورفورغليبرون (لوسيورفور) أقراص 0.8–17.2 ملغ | دواء جينيريك لاوسي فموي GLP-1 | GLT

جينيريك أورفورغليبرون من Lucius Pharmaceuticals (لاوس)، نظام معايرة من 6 جرعات لإدارة الوزن